Related Experiment Video
Updated: Feb 7, 2026

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
Published on: July 3, 2020
Stanniocalcin 2 Ameliorates Hepatosteatosis Through Activation of STAT3 Signaling
Jiejie Zhao1,2, Yang Jiao1,2, Yuping Song3
1Department of Endocrinology and Metabolism, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Abstract:
Stanniocalcin 2 (STC2), a secreted glycoprotein hormone, regulates many biological processes, including cell proliferation, apoptosis, tumorigenesis, and atherosclerosis. However, its role in hepatic triglyceride metabolism remains unknown. In the present study, we found that expression levels of STC2 were significantly reduced in the livers of leptin-deficient and high fat diet-induced obese mice. Systemic administration of STC2 recombinant protein or adenovirus-mediated overexpression of STC2 markedly attenuated hepatosteatosis and hypertriglyceridemia in obese mice. At the molecular level, we found that STC2 activated the STAT3 signaling pathway to inhibit lipogenic gene expression. Consistently, in vitro studies further showed that inhibition of STAT3 signaling abolished the anti-steatotic effects of STC2. Together, our results revealed an important role of STC2 in the regulation of hepatic triglyceride metabolism, which might provide a potential therapeutic target for the treatment of fatty liver and related metabolic disorders.
Insights
Stanniocalcin 2 (STC2) deficiency worsens fatty liver in obese mice. STC2 administration reduces liver fat and triglycerides by inhibiting fat-producing genes via the STAT3 pathway.
Area of Science:
- Endocrinology
- Metabolic research
- Molecular biology
Background:
- Stanniocalcin 2 (STC2) is a secreted glycoprotein hormone involved in various biological processes.
- The role of STC2 in hepatic triglyceride metabolism and its potential link to obesity-related liver diseases are currently unknown.
Purpose of the Study:
- To investigate the role of STC2 in regulating hepatic triglyceride metabolism.
- To explore STC2 as a potential therapeutic target for fatty liver disease.
Main Methods:
- Studied STC2 expression in livers of obese mouse models (leptin-deficient and high-fat diet-induced).
- Administered STC2 recombinant protein and used adenovirus-mediated STC2 overexpression in obese mice.
- Investigated the effect of STC2 on lipogenic gene expression and the STAT3 signaling pathway both *in vivo* and *in vitro*.
Main Results:
- STC2 expression was significantly reduced in the livers of obese mice.
- STC2 administration or overexpression attenuated hepatosteatosis and hypertriglyceridemia in obese mice.
- STC2 activated the STAT3 signaling pathway, leading to inhibition of lipogenic gene expression; STAT3 inhibition abolished STC2's anti-steatotic effects.
Conclusions:
- STC2 plays a crucial role in regulating hepatic triglyceride metabolism.
- STC2 demonstrates potential as a therapeutic target for fatty liver and associated metabolic disorders.
Related Concept Videos
Endocrine Signaling
Yeast Signaling
What is Cell Signaling?
Intracellular Signaling Cascades
Bacterial Signaling
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3

